Isatuximab in addition to bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma – first line
Isatuximab in addition to bortezomib, lenalidomide and dexamethasone is currently in clinical development as a first-line therapy option for patients with newly diagnosed multiple myeloma (MM) who are not eligible for autologous stem cell transplant (ASCT). MM may or may not be symptomatic in the early stages, but eventually leads to a range of problems. It is often diagnosed after a routine blood or urine test. The symptoms of myeloma may include: bone pain, bone fractures and spinal cord compression, anaemia, repeated infections, raised calcium levels in the blood, and kidney function impairment. The current first-line treatment option is high dose combination chemotherapy followed ASCT for which some patients may be ineligible.
Isatuximab is an anti-CD38 monoclonal antibody with a multi-modal action for killing tumor cells via direct tumor targeting and immune cell engagement. On review and approval, isatuximab in addition to standard combination chemotherapy treatment with bortezomib, lenalidomide and dexamethasone will offer an additional first-line treatment option for patients with newly diagnosed MM who are not eligible for ASCT.